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ABSTRACT
Objective: The objective of this research was to determine early advanced glycation end-product (AGE) inhibition by natural aldose reductase 
inhibitors (ARIs), quercetin and catechin.
Methods: The assay mixture (4 ml) consisted of 2 ml of 50 mM phosphate-buffered saline (pH 7.4), 50 µg/µl bovine serum albumin (BSA), and 2 mM 
glucose with or without the inhibitor. The test samples were treated with three different concentrations (10 mM, 20 mM, and 40 mM) of quercetin 
and catechin. High-throughput screening-based assay was adapted to perform the BSA-glucose test to determine the induction of AGE formation and 
its inhibition by quercetin, and catechin, using the fluorescence of the AGE-BSA sample at excitation and emission wavelengths of 350 and 450 nm.
Result: The ARIs, quercetin and catechin inhibited early glycation with an inhibitory concentration value of 15.58 mM and 35.01 mM, respectively.
Conclusion: The suppression of AGEs formation by natural inhibitors of aldose reductase would provide an alternative approach to the control of 
diabetic complications.
Keywords: Aldose reductase inhibitors, Advanced glycation end-products, High-throughput virtual screening, Natural compounds, Diabetic 
complications.
INTRODUCTION
Diabetes is a life-threatening metabolic disorder, causing 1.5 million 
deaths per year worldwide [1]. One of the two patients with diabetes 
is diagnosed with complications, ranging from one to several [2], 
caused due to chronic hyperglycemia and inadequate treatment. The 
non-enzymatic glycation between the sugar and the protein is related 
to the development of diabetic complications. Advanced glycation 
end-products (AGEs), the products of glycation, are generated in 
response to the stimulations from different triggering mechanisms. 
The receptor of AGE (RAGE), being a signal transduction receptor, can 
activate various signal transduction cascades. AGE-RAGE interaction 
modulates the expression of various proinflammatory molecules. 
AGE-RAGE interaction activates nuclear factor-kappa B (NF-κB) and 
the key target of reactive oxygen species (ROS) generation in the cell. 
Furthermore, the upregulation of NF-κB further stimulates RAGE 
generation. Apart from RAGE activation, ROS generation and generation 
of AGE cause activation of the polyol pathway by the induction of aldose 
reductase (ALR2) and the rate-limiting enzyme of the pathway. The 
3-deoxyglucosone produced as a by-product from the polyol pathway 
is a major precursor of AGE. Hyperglycemia-induced activation of ALR2 
increases AGE production that in turn stimulate further activation of 
ALR2 [3].
The activation of polyol pathway, increased production of AGEs, NF-
κB activation, activation of protein kinase C, and oxidative stress are 
the main causes for the hyperglycemia induced vascular damage 
and the occurrence of diabetic complications. Although many factors 
could be responsible for the pathogenesis of diabetic complications, 
accumulation of AGEs plays the main role in inflammation, diabetes, 
and aging [4].
Glucose is a potent glycation agent and fructose, the by-product of 
the polyol pathway, causes severe glycation than glucose. AGE is 
increasingly found in the extracellular matrix, and the increased 
production of intracellular AGE precursors cause devastating effects in 
the body. Initially, a Schiff base is formed by the non-enzymatic reaction 
between the aldehyde group of sugar and the amino group of the 
protein. The rearrangement of Schiff base produces Amadori products 
that undergo rearrangements to form stable AGEs. This reaction is 
called Maillard reaction [5]. The formation of dicarbonyls such as 
3-deoxyglucosone, methylglyoxal (MGO) and glyoxal occur in early 
glycation. The generation of the dicarbonyls, the advanced glycation 
precursors, occurs as early as 3 weeks due to slow degradation of 
glucose at 37°C. Short increase in glucose level also provoked an 
increase in the generation of advanced glycation precursors [6]. In 
prolonged hyperglycemia, increased amounts of AGEs are found in the 
extracellular matrix causing a severe impact on the cellular function [7]. 
Damage is mainly due to the modification and mutation of intracellular 
proteins and the binding of modified plasma proteins to the RAGE, a 
signal transduction receptor found on the vascular endothelial cells and 
smooth muscle cells. Modification of intracellular proteins and plasma 
proteins damage the cell by the induction of ROS which in turn activates 
the NF-κB and upregulates the inflammatory pathways, causing several 
pathological changes [8].
The Maillard reaction is the resultant of the nonenzymatic reaction 
occurring between the proteins and the reducing sugars. A reducing 
sugar like glucose reacts with the amines to form unstable, Schiff 
base that rearranges to form stable amadori product. Dicarbonyl 
compounds, MGO, and deoxyglucosone are the resultant of the chemical 
transformation of the amadori products. During the last stages of 
glycation, AGEs are formed due to the oxidation and dehydration 
reactions which could cause several diabetic complications. AGEs are 
associated with diseases such as diabetes, renal failure, and cancers. 
The accumulation of AGEs on the proteins impairs the protein function 
and activity by mutating it. Increased AGE concentration in the tissue 
and the plasma compromises the antioxidant defense system causing 
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2017.v10i11.19412.
Research Article
174
Asian J Pharm Clin Res, Vol 10, Issue 11, 2017, 173-176
 Julius and Hopper 
deleterious effects in the body [9]. Since the discovery of Maillard 
reaction and the deleterious damage, it causes to the body, progress 
in identifying inhibitors that could inhibit nonenzymatic browning of 
proteins are of great interest [10].
The bovine serum albumin (BSA)-glucose test is a prominent method 
for detecting the amount of AGEs generated, using its fluorescence at 
excitation and emission wavelengths of 350 and 450 nm [11]. Induction 
of AGEs and its inhibition by the plant extracts or the pure compound 
could be used effectively to determine the AGE inhibition property of 
the compounds.
Traditional medicine has used different sources of food that act as 
natural free radical scavengers to cure various diseases. Several natural 
and synthetic inhibitors of ALR2 and AGEs show effective prevention 
of diabetic complications in vivo with experimental models and clinical 
trials [12]. Quercetin, luteolin, and kaempferol, the flavonoids from 
the whole plant extract of Saraca indica, proved to have rat lens ALR2 
inhibiting activity. The structure-activity relationship of the flavonoids 
inhibiting both ALR2 and AGEs has been studied to identify natural 
compounds that could potentially inhibit both the factors.
Treatment using natural medicines is preferred as an alternative source 
for treating aging and diabetes. Herbal medicines are used extensively 
for preventing and treating diseases since they possess antidiabetic, 
antihyperlipidemic, and anti-inflammatory properties [13,14]. Early 
glycation can be prevented by preventing the formation of precursors 
of AGEs. Polyphenols such as genistein, naringin, and ellagic acid are 
reported to control aldehyde-induced glycation and prevention of the 
formation of AGE precursors [15]. This work adapts a cost-effective 
high-throughput screening-based assay to identify the potency of 
aldose reductase inhibitors (ARIs), quercetin, and catechin in the 
prevention of early AGEs [16].
METHODS
All the chemicals from were purchased from Sigma-Aldrich.
AGE inhibition assay
The measurement of AGE formation and its inhibition by test compounds 
were performed according to Matsuura et al. [17]. The inhibition of the 
Maillard reaction by the test samples was determined by the decrease 
in fluorescence in comparison with the positive control without the 
drug treatment. The pure compounds, quercetin and catechin, were 
dissolved in dimethyl sulfoxide. The assay mixture (4 ml) consisted of 
2 ml of 50 mM phosphate-buffered saline (PBS) (pH 7.4), 50 µg/µl BSA, 
and 2 mM glucose with or without the inhibitor. The negative control 
was prepared without the glucose and the inhibitor. Positive control 
did not contain the inhibitor. The test samples were treated with three 
different concentrations (10 mM, 20 mM, and 40 mM) of quercetin 
and catechin. The negative control (blank) was kept at 4°C until 
measurement. The assay mixtures were incubated for 24 hrs in the 
dark. 500 µl of the aliquots were transformed to 1.5 ml Eppendorf 
Tube, and 50 µl of 100% trichloroacetic acid was added. The contents 
were vortexed and centrifuged at 15000 rpm at 4°C for 4 minutes. The 
supernatant was discarded, and the AGE-BSA precipitate was dissolved 
in 1 ml of PBS, and the samples were screened using spectrofluorometer 
to determine AGE formation in the sample. The samples were loaded 
in triplicates to a 96-well black plate. Changes in the intensity of the 
fluorescence detected in the test samples were compared with the 
fluorescence of the untreated control. The fluorescence end point was 
read at excitation, 360 and emission, 460 wavelengths and was directly 
proportional to the AGEs in the sample.
The inhibition percentage of AGE was calculated by the formula:
( )Positivecontrol test






AGE inhibition was determined for the two known natural ARIs, 
quercetin and catechin. Table 1 lists the AGE inhibition assay reaction 
contents and quantities. Inhibitory concentration (IC50) was calculated 
by plotting the concentration of the compound against its inhibition, 
using linear regression graph. IC50 was calculated using the slope of the 
graph. Better fit of the regression line was observed with regression 
values (R2) of 0.96 and 1 for quercetin and catechin, respectively. 
The experiment was repeated thrice for concordancy. IC50 values of 
quercetin and catechin were 15.58 mM and 35.01 mM, respectively. 
Fig. 1 illustrates the percent inhibition of AGE by quercetin and catechin 
at three different concentrations.
DISCUSSION
Hyperglycemia induces the formation of AGEs through various 
pathways, including the polyol pathway. The activation of ALR2 and the 
first rate-limiting enzyme of the polyol pathway have been reported to 
be involved in increased generation of AGEs. Diet, rich in protein and 
fat, is the external source of AGEs that is proportional to the increased 
serum levels of AGE which contribute to the crosslinking of the proteins, 
worsening the complications in patients with diabetes [18]. Increased 
expression of mitogen-activated protein kinases, NF-κB, and vascular 
cell adhesion molecule have occurred in patients with AGE-rich diet, 
indicating the probability of proliferative diseases [19]. Crude plant 
extracts reported having AGE inhibition activity have been successful 
in the control and management of diabetes and its complications along 
with regulating blood glucose [20]. Although most of the synthetic 
inhibitors of AGEs were withdrawn due to side effects, phenolic 
compounds present in plants which are identified to have potential AGE 
inhibiting activity [21,22]. The whole plant extracts of Ligularia fischeri 
were reported to have ALR2, AGEs inhibition, and radical scavenging 
activity, contributed by the compound 3, 4-dicaffeoylquinic acid [23]. 
Glycyrrhiza glabra, Withania somnifera, Petroselinum crispum, and 
Terminalia chebula have shown benefecial effects in the treatment of 
diabetes and complications by inhibiting the formation of AGEs [24]. 
Eugenol, a phenylpropanoid from Ocimum Gratissimum, is an FDA-
approved inhibitor of AGE that can be used for the management of 
diabetes and complications [25]. Compounds with AGE inhibiting 
property also act as natural ROS scavengers [26,27]. Polyol pathway-
induced AGE formation might be controlled by inhibiting the activity 
of ALR2. Natural ALR2 inhibitors with AGE suppressing potency and 
antioxidant properties would be a three-sided useful approach to control 
diabetic complications. Dietary flavonoids are used to suppress or 
control the occurrence of chronic diseases such as cancers and diabetes 
by preventing ROS formation and by supplying antioxidants that would 
Table 1: Reaction contents of AGE inhibition assay
Reagents Positive control Negative control Q 10 mM Q 20 mM Q 40 mM C 10 mM C 20 mM C 40 mM
PBS (ml) 2 2 2 2 2 2 2 2
BSA (50 mg/ ml) 800 800 800 800 800 800 800 800
2 mM Glucose (µl) 400 0 400 400 400 400 400 400
Inhibitor (µl) 0 0 800 800 800 800 800 800
Distilled water (µl) 800 1200 0 0 0 0 0 0
Q: Quercetin, C: Catechin, AGEs: Advanced glycation end-products, BSA: Bovine serum albumin, PBS: Phosphate-buffered saline
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quench the ROS. Increasing the antioxidant defense system would 
suppress the damage by the ROS in the human body. The flavonoids, 
quercetin, and catechin had antioxidant property, antiproliferative 
activity, and antioxidant properties [28] when tested on cancer cell 
lines of colon (Caco-2) breast (MCF-7), and pancreas (BxPC-3) [29]. The 
potency of quercetin and catechin to inhibit ALR2 [30,31] is already 
well known, and this study reveals their potential in suppressing the 
formation of AGEs in a 24 hrs early glycation assay involving BSA and 
glucose.
Accumulation of AGE during hyperglycemia and its degradation 
with proper glycemic control indicate the induction of AGE during 
hyperglycemia. AGE-RAGE formation, further, accelerates the formation 
of AGE, during hyperglycemia [32]. Furthermore, AGE-RAGE-induced 
ROS generation causes worsening of vascular complications in diabetic 
patients. Progression of diabetic nephropathy has been controlled 
by preventing ROS production induced by cytosolic AGE-RAGE, 
inhibiting mitochondrial superoxide production in hyperglycemic 
conditions [33]. Therefore, the importance of the suppression or control 
of AGE formation during hyperglycemia is vital to prevent worsening 
of the disease. In this study, quercetin and catechin, the known natural 
inhibitors of ALR2, were assayed for AGE inhibition, induced using 
incubation of BSA with glucose. The fluorescence was proportional to 
the formation of yellow AGE-BSA precipitate that decreased with the 
treatment of quercetin and catechin over incubation. Although various 
attempts have been made to identify effective glycation inhibitors, and 
few natural compounds have been proven to suppress AGE production, 
after the discovery of aminoguanidine that had the capacity to prevent 
the diabetes-induced formation of AGEs. The suppression of AGEs 
formation by natural inhibitors of ALR2 such as quercetin and catechin 
would provide an alternative approach to the control of diabetic 
complications.
CONCLUSION
Diabetic complications have been a major problem more than diabetes 
itself since it affects both small and large blood vessels, causing 
deleterious effects. The pathology of diabetic complications is caused 
due to multiple factors, among which activation of polyol pathway, 
generation of AGEs and ROS plays a vital role. ALR2 inhibiting flavonoids, 
quercetin and catechin inhibit AGE formation at IC50 concentrations of 
15.58 mM and 35.01 mM, respectively. This indicates the potency of 
quercetin and catechin as AGE inhibitors, apart from ALR2 inhibition, 
which could be used to suppress diabetes-induced AGE formation and 
to control worsening of diabetic complications.
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